Sky Century Investment (SKYI) Shares Outstanding (Weighted Average) (2012 - 2026)
Sky Century Investment (SKYI) reported Shares Outstanding (Weighted Average) of $2.2 million for Q1 2026, down 98.99% year-over-year from $221.7 million in Q1 2025, and down 99.0% quarter-over-quarter from $223.5 million in Q4 2025.
Sky Century Investment (SKYI) Shares Outstanding (Weighted Average) (2012 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $2.2 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $2.2 million, down 98.99% year-over-year; the trailing twelve-month figure through Feb 2026 was $2.2 million (down 98.99% YoY), and the FY2025 annual result was $222.6 million, up 0.91% from the prior year.
- Shares Outstanding (Weighted Average) slipped to $2.2 million in Q1 2026 per SKYI's latest filing, from $223.5 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $223.5 million in Q2 2025 and troughed at $2.2 million in Q1 2026.
- A 3-year average of $197.4 million and a median of $220.6 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) advanced 1.32% in 2025, then slumped 98.99% in 2026.
- A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $220.6 million in 2024, then climbed by 1.32% to $223.5 million in 2025, then slumped by 99.0% to $2.2 million in 2026.
- Business Quant data shows SKYI's Shares Outstanding (Weighted Average) at $2.2 million in Q1 2026, $223.5 million in Q4 2025, and $222.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 100.50 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | 5.11 Bn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 64.74 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 88.01 Mn |
| 10 | Sky Century Investment | - | - | 31,666.00 | 2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 2.24 Mn |
| Nov 30, 2025 | 223.55 Mn |
| Aug 31, 2025 | 222.65 Mn |
| May 31, 2025 | 223.55 Mn |
| Feb 28, 2025 | 221.73 Mn |
| Nov 30, 2024 | 220.64 Mn |
| Aug 31, 2024 | 220.64 Mn |
| May 31, 2024 | 220.64 Mn |
| Feb 29, 2024 | 220.64 Mn |
| Aug 31, 2014 | 110.02 Mn |
| May 31, 2014 | 101.80 Mn |
| Feb 28, 2014 | 110.02 Mn |
| Nov 30, 2013 | 110.02 Mn |
| Aug 31, 2013 | 76.20 Mn |
| May 31, 2013 | 60.00 Mn |
| Feb 28, 2013 | 1.12 Bn |
| Aug 31, 2012 | 6.00 Mn |
| May 31, 2012 | 222,222.00 |